Literature DB >> 3542077

The kinetics of immune reconstitution after human marrow transplantation.

L G Lum.   

Abstract

Human marrow transplantation for the treatment of malignant and nonmalignant disorders is becoming an established modality of therapy. As in any aggressive therapeutic modality, the benefits must be balanced with the risks of the therapy. The aggressive chemoradiotherapy used to prepare patients for marrow transplantation creates a transient immunodeficiency disorder postgrafting until the transferred donor marrow reestablishes a competent immune system. Immune reconstitution posttransplant follows a general pattern developing from immature to mature immune functions. Immune reactivity during the first month postgrafting is extremely low. Cytotoxic and phagocytic functions recover by day 100, while more specialized and cooperative functions of T and B cells remain impaired up to one year or more postgrafting. After the first year postgrafting, the various components of the immune systems of most healthy marrow recipients begin to work synchronously, whereas the immune systems of recipients with chronic graft-v-host disease (GVHD) remain crippled. Recent evidence shows that transfer of specific immunity from marrow donors to marrow recipients plays a role in reestablishing immunocompetence. Transferred antigen-specific immunity may explain why more recipients do not die from overwhelming infections.

Entities:  

Mesh:

Year:  1987        PMID: 3542077

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  56 in total

Review 1.  Post-transplant immune recovery and the implication for infection risk.

Authors:  Michael E Trigg
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 2.  Hematopoietic stem cell transplantation: a primer for the primary care physician.

Authors:  Chantal S Léger; Thomas J Nevill
Journal:  CMAJ       Date:  2004-05-11       Impact factor: 8.262

3.  Impaired pulmonary immunity post-bone marrow transplant.

Authors:  Stephanie M Coomes; Leah L N Hubbard; Bethany B Moore
Journal:  Immunol Res       Date:  2011-05       Impact factor: 2.829

Review 4.  [Is the administration of immunoglobulins following bone marrow transplantation indicated?].

Authors:  H G Klingemann
Journal:  Klin Wochenschr       Date:  1987-09-15

Review 5.  Hematologic aspects of myeloablative therapy and bone marrow transplantation.

Authors:  Roger S Riley; Michael Idowu; Alden Chesney; Shawn Zhao; John McCarty; Lawrence S Lamb; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

Review 6.  Eicosanoid regulation of pulmonary innate immunity post-hematopoietic stem cell transplantation.

Authors:  Megan N Ballinger; Tracy R McMillan; Bethany B Moore
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2007 Jan-Feb       Impact factor: 4.291

Review 7.  Reduction in transplant-related complications in patients given intravenous immuno globulin after allogeneic marrow transplantation.

Authors:  M F Siadak; K Kopecky; K M Sullivan
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

8.  Analysis of different protein kinase C-dependent events in T cells from allogeneic bone marrow transplantation recipients.

Authors:  M A Balboa; M Izquierdo; F Sánchez-Madrid; J M Fernández-Rañada; M López-Botet
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

9.  Immunization with Haemophilus influenzae type b conjugate vaccine in children given bone marrow transplantation: comparison with healthy age-matched controls.

Authors:  M A Avanzini; A M Carrà; R Maccario; M Zecca; G Zecca; A Pession; P Comoli; M Bozzola; A Prete; R Esposito; F Bonetti; F Locatelli
Journal:  J Clin Immunol       Date:  1998-05       Impact factor: 8.317

10.  Investigation and management of pulmonary infiltrates following bone marrow transplantation: an eight year review.

Authors:  J H Campbell; N Blessing; A K Burnett; R D Stevenson
Journal:  Thorax       Date:  1993-12       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.